Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C18H21F3N6O2.ClH |
| Molecular Weight | 446.854 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.NC1=NC=C(C2=CC(=NC(=N2)N3CCOCC3)N4CCOCC4)C(=C1)C(F)(F)F
InChI
InChIKey=DGPLYAXBXJXEID-UHFFFAOYSA-N
InChI=1S/C18H21F3N6O2.ClH/c19-18(20,21)13-9-15(22)23-11-12(13)14-10-16(26-1-5-28-6-2-26)25-17(24-14)27-3-7-29-8-4-27;/h9-11H,1-8H2,(H2,22,23);1H
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C18H21F3N6O2 |
| Molecular Weight | 410.3935 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: Description was created using several sources including: https://www.ncbi.nlm.nih.gov/pubmed/?term=22065080 | https://www.ncbi.nlm.nih.gov/pubmed/?term=26846842
Curator's Comment: Description was created using several sources including: https://www.ncbi.nlm.nih.gov/pubmed/?term=22065080 | https://www.ncbi.nlm.nih.gov/pubmed/?term=26846842
Buparlisib (NVP-BKM12), a dimorpholino pyrimidine derivative, is a selective pan class I phosphatidylinositol-3 kinase (PI3K) inhibitor for treating cancer. It penetrates the blood-brain barrier and has a potential as a glioma treatment. NVP-BKM120 inhibits PI3K activity by binding to the ATP binding cleft of this enzymes and was tested against class I PI3K and other kinases using an ATP depletion (Kinase-Glo) assay. The compound was shown to be active against P110 α, β, γ and δ. The inhibition of the PI3K signaling pathways leads to different forms of cell death on the basis of p53 statuses. Buparlisib demonstrated its activity in human glioblastoma (GBM) cells in vitro and in vivo and is in clinical trials for solid tumors including GBM.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P42336 Gene ID: 5290.0 Gene Symbol: PIK3CA Target Organism: Homo sapiens (Human) |
35.0 nM [IC50] | ||
Target ID: P42338 Gene ID: 5291.0 Gene Symbol: PIK3CB Target Organism: Homo sapiens (Human) |
175.0 nM [IC50] | ||
Target ID: P48736 Gene ID: 5294.0 Gene Symbol: PIK3CG Target Organism: Homo sapiens (Human) |
348.0 nM [IC50] | ||
Target ID: O00329 Gene ID: 5293.0 Gene Symbol: PIK3CD Target Organism: Homo sapiens (Human) |
108.0 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. | 2012 Feb |
|
| Antitumor activity of NVP-BKM120--a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells. | 2012 Jan 1 |
|
| BKM-120 (Buparlisib): A Phosphatidyl-Inositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma. | 2016 Feb 5 |
Sample Use Guides
In diagnosed patients with non-small cell lung cancer (NSCLC) that progressed after one prior, platinum-based chemotherapy line for metastatic disease or after one or two prior antineoplastic therapy lines for metastatic disease buparlisib was administered in on a continuous once daily dosing schedule at a dose of 100 mg. The patient was dosed on a flat scale of mg/day and not adjusted to body weight or body surface area.
Route of Administration:
Oral
The biologic effects of a selective PI3K inhibitor NVP-BKM120 (Buparlisib) were studied in a set of 21 glioma cell lines that differed in terms of the mutational statuses of PTEN and p53. Cells treatment for 72 hours resulted in a dose-dependent growth inhibition and effectively blocked the PI3K/Akt signaling cascade. NVP-BKM120 potently inhibited glioma cell proliferation in all the lines, with IC50 values in the cell viability assay of 1 to 2 uM.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 19:42:29 UTC 2023
by
admin
on
Fri Dec 15 19:42:29 UTC 2023
|
| Record UNII |
194LK4P5K1
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C1404
Created by
admin on Fri Dec 15 19:42:29 UTC 2023 , Edited by admin on Fri Dec 15 19:42:29 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1312445-63-8
Created by
admin on Fri Dec 15 19:42:29 UTC 2023 , Edited by admin on Fri Dec 15 19:42:29 UTC 2023
|
PRIMARY | |||
|
194LK4P5K1
Created by
admin on Fri Dec 15 19:42:29 UTC 2023 , Edited by admin on Fri Dec 15 19:42:29 UTC 2023
|
PRIMARY | |||
|
CHEMBL2017974
Created by
admin on Fri Dec 15 19:42:29 UTC 2023 , Edited by admin on Fri Dec 15 19:42:29 UTC 2023
|
PRIMARY | |||
|
DBSALT002043
Created by
admin on Fri Dec 15 19:42:29 UTC 2023 , Edited by admin on Fri Dec 15 19:42:29 UTC 2023
|
PRIMARY | |||
|
AB-30
Created by
admin on Fri Dec 15 19:42:29 UTC 2023 , Edited by admin on Fri Dec 15 19:42:29 UTC 2023
|
PRIMARY | |||
|
66577015
Created by
admin on Fri Dec 15 19:42:29 UTC 2023 , Edited by admin on Fri Dec 15 19:42:29 UTC 2023
|
PRIMARY | |||
|
DTXSID50156980
Created by
admin on Fri Dec 15 19:42:29 UTC 2023 , Edited by admin on Fri Dec 15 19:42:29 UTC 2023
|
PRIMARY | |||
|
C142973
Created by
admin on Fri Dec 15 19:42:29 UTC 2023 , Edited by admin on Fri Dec 15 19:42:29 UTC 2023
|
PRIMARY | |||
|
71954
Created by
admin on Fri Dec 15 19:42:29 UTC 2023 , Edited by admin on Fri Dec 15 19:42:29 UTC 2023
|
PRIMARY | |||
|
100000175841
Created by
admin on Fri Dec 15 19:42:29 UTC 2023 , Edited by admin on Fri Dec 15 19:42:29 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |